Literature DB >> 22060188

Radiation induces up-regulation of somatostatin receptors 1, 2, and 5 in small cell lung cancer in vitro also at low absorbed doses.

Jenny Oddstig1, Peter Bernhardt, Ola Nilsson, Håkan Ahlman, Eva Forssell-Aronsson.   

Abstract

BACKGROUND: Radiation can be used to up-regulate the expression of the somatostatin receptor (sstr) subtype 2 in small cell lung cancer (SCLC) cells at absorbed doses of 2-8 Gy. Increased sstr expression results in increased binding of radiolabeled somatostatin analogs to the tumor cell, which enhances the efficacy of systemic radionuclide therapy. The aim of this study was to determine if lower absorbed doses could up-regulate sstr2 expression, and possibly influence other sstr subtypes.
METHODS: Human H69 SCLC cells were irradiated with an absorbed dose of 0.12-6.0 Gy and the sstr mRNA expression 3 days after irradiation was measured by quantitative real-time polymerase chain reaction for sstr1-5. At the same time point was the binding of [(177)Lu]-DOTA(0)-Tyr(3)-octreotate to the cells measured after irradiation to an absorbed dose of 0.12-2.0 Gy and compared to the binding to nonirradiated cells.
RESULTS: mRNA expression of sstr1, sstr2, and sstr5 was increased by a factor of 1.5-2 in cells irradiated with absorbed doses≥4 Gy and the binding of [(177)Lu]-DOTA(0)-Tyr(3)-octreotate was, accordingly, 2-3 times higher to irradiated cells for all absorbed doses, except 0.25 Gy.
CONCLUSION: The binding of [(177)Lu]-DOTA(0)-Tyr(3)-octreotate was increased after radiation exposure. This increase was observed at low absorbed doses in parallel with up-regulation of sstr1, sstr2, and sstr5 mRNA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22060188     DOI: 10.1089/cbr.2010.0921

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  8 in total

Review 1.  Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.

Authors:  Samuel Adant; Girish M Shah; Jean-Mathieu Beauregard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-06       Impact factor: 9.236

2.  Priming increases the anti-tumor effect and therapeutic window of 177Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1.

Authors:  Johanna Dalmo; Johan Spetz; Mikael Montelius; Britta Langen; Yvonne Arvidsson; Henrik Johansson; Toshima Z Parris; Khalil Helou; Bo Wängberg; Ola Nilsson; Maria Ljungberg; Eva Forssell-Aronsson
Journal:  EJNMMI Res       Date:  2017-01-05       Impact factor: 3.138

Review 3.  Somatostatin receptors as a new active targeting sites for nanoparticles.

Authors:  Ahmed A H Abdellatif; Sa'ed M Aldalaen; Waleed Faisal; Hesham M Tawfeek
Journal:  Saudi Pharm J       Date:  2018-05-31       Impact factor: 4.330

4.  Hyperfractionated Treatment with 177Lu-Octreotate Increases Tumor Response in Human Small-Intestine Neuroendocrine GOT1 Tumor Model.

Authors:  Mikael Elvborn; Emman Shubbar; Eva Forssell-Aronsson
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

5.  Somatostatin Receptor Theranostics for Refractory Meningiomas.

Authors:  Betty Salgues; Thomas Graillon; Tatiana Horowitz; Olivier Chinot; Laetitia Padovani; David Taïeb; Eric Guedj
Journal:  Curr Oncol       Date:  2022-08-04       Impact factor: 3.109

Review 6.  Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer.

Authors:  Tyrillshall S T Damiana; Simone U Dalm
Journal:  Pharmaceutics       Date:  2021-05-07       Impact factor: 6.321

Review 7.  Down-regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5: a novel mechanism for inhibition of cellular proliferation and insulin secretion by somatostatin.

Authors:  Guisheng Zhou; Jim Sinnett-Smith; Shi-He Liu; Juehua Yu; James Wu; Robbi Sanchez; Stephen J Pandol; Ravinder Abrol; John Nemunaitis; Enrique Rozengurt; F Charles Brunicardi
Journal:  Front Physiol       Date:  2014-06-25       Impact factor: 4.566

8.  Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma.

Authors:  Philipp E Hartrampf; Heribert Hänscheid; Olivia Kertels; Andreas Schirbel; Michael C Kreissl; Michael Flentje; Reinhart A Sweeney; Andreas K Buck; Bülent Polat; Constantin Lapa
Journal:  Clin Transl Radiat Oncol       Date:  2020-03-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.